Market Overview

UPDATE: Oppenheimer Initiates Coverage on Karyopharm Therapeutics on Novel Mechanism with Broad Applicability in Oncology


In a report published Monday, Oppenheimer analyst David Ferreiro initiated coverage on Karyopharm Therapeutics (NASDAQ: KPTI) with an Outperform rating and $23.00 price target.

In the report, Oppenheimer noted, “Karyopharm Therapeutics (KPTI) is focused on the development of novel small-molecule therapeutics targeting the nuclear export protein XPO1. KPTI's lead asset Selinexor has demonstrated anti-cancer activity across a wide variety of cancer types. The company appears on track to initiate pivotal trials for three hematological malignancies in 1H14. Of the three, we believe Selinexor's greatest potential is in elderly acute myeloid leukemia (AML), a difficult-to-treat disease with few effective therapies available. Given its novel mechanism, we see broad potential for Selinexor across multiple cancer indications (including solid tumors), as well as potential for combination with other targeted therapies. We are initiating coverage with an Outperform rating, and a price target of $23.”

Karyopharm Therapeutics closed on Friday at $16.29.

Latest Ratings for KPTI

Jul 2020Morgan StanleyInitiates Coverage OnOverweight
Jun 2020WedbushMaintainsNeutral
Jun 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for KPTI
View the Latest Analyst Ratings


Related Articles (KPTI)

View Comments and Join the Discussion!

Posted-In: David Ferreiro OppenheimerAnalyst Color Initiation Analyst Ratings

Latest Ratings

SOLOAegis CapitalAssumes4.0
TSLAJP MorganMaintains295.0
PFSICredit SuisseMaintains46.0
PMTCredit SuisseMaintains22.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at